Why did 2627.HK stock jump today?

2627.HK stock jumped **27.50%** on 11 Mar 2026 driven by heavy volume (**3,657,650.00**) and momentum above the 50-day average; sector comparisons and market attention to vaccine peers likely amplified buying.

What are the main risks for 2627.HK stock?

Main risks for 2627.HK stock include negative EPS (**-0.65**), low current ratio (**0.44**), long receivable days and high valuation multiples versus peers, which can magnify downside if milestones slip.

How does Meyka AI view 2627.HK stock?

Meyka AI rates 2627.HK **64.57/100 (B, HOLD)**, balancing strong technical momentum against weak near-term fundamentals; the platform’s forecasts show mixed shorter-term and stronger longer-term potential.

What price targets or forecast exist for 2627.HK stock?

Meyka AI's forecast model projects yearly **HK$48.72**, 3-year **HK$67.13**, 5-year **HK$85.38** and 7-year **HK$113.27**; compare these to the current **HK$71.40** for implied upside or downside.

HK Stocks

Up 27.50%: 2627.HK stock HK$71.40 market close Hong Kong: catalysts

ByDanny Kontos March 11, 2026

Ab&B Bio-Tech Co Ltd. (2627.HK) rallied 27.50% to HK$71.40 at market close on 11 Mar 2026 in Hong Kong, making it one of the top gainers on the HKSE. Volume surged to 3,657,650.00 shares versus an average of 314,790.00, suggesting elevated buying interest. The move outpaced the healthcare sector, which showed modest gains, and lifted the stock well above its 50-day average of HK$48.68. Market closed data and this intraday jump point to short-term momentum; we examine catalysts, fundamentals, technicals and risks for 2627.HK stock below.